KLRS
Kalaris Therapeutics

111
Mkt Cap
$182.16M
Volume
62,878.00
52W High
$12.90
52W Low
$2.14
PE Ratio
-1.33
KLRS Fundamentals
Price
$9.81
Prev Close
$9.74
Open
$9.56
50D MA
$7.56
Beta
0.94
Avg. Volume
180,486.82
EPS (Annual)
-$11.73
P/B
4.38
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by Brokerages
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat.com reports...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1%
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 503,479...
MarketBeat·21d ago
News Placeholder
Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy
Chardan Capital raised Kalaris Therapeutics to a "strong-buy" rating in a research note on Tuesday...
MarketBeat·28d ago
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts
Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are presently covering the firm, MarketBeat.com...
MarketBeat·29d ago
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Monday Sector Laggards: Biotechnology, Electronic Equipment & Products
In trading on Monday, biotechnology shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Quince Therapeutics, down about 16.2% and shares of Kalaris...
Nasdaq News: Markets·2mo ago
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five research firms that are covering the company, Marketbeat.com...
MarketBeat·2mo ago
News Placeholder
Leerink Partnrs Issues Pessimistic Outlook for KLRS Earnings
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) - Research analysts at Leerink Partnrs dropped their Q4 2025 EPS estimates for Kalaris Therapeutics in a report issued on Monday, November 17th...
MarketBeat·2mo ago
News Placeholder
What is William Blair's Estimate for KLRS FY2025 Earnings?
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) - Research analysts at William Blair decreased their FY2025 earnings per share estimates for shares of Kalaris Therapeutics in a research note...
MarketBeat·2mo ago
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of...
MarketBeat·2mo ago
<
1
2
...
>

Latest KLRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.